Stem cell research

Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration

Retrieved on: 
Tuesday, June 29, 2021

Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.

Key Points: 
  • Boston Childrens Hospital, which has the largest National Institutes of Health-funded pediatric research enterprise in the United States, and ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Childrens Hospital with an introduction to Boston Childrens translational research capabilities.
  • The agreement enables Boston Childrens and ElevateBio to form multiple cell and gene therapy companies together; provides Boston Childrens researchers access to ElevateBios core-enabling technologies, manufacturing, and leading expertise to advance their programs; and will guarantee Boston Childrens researchers dedicated viral-vector manufacturing space at ElevateBio BaseCamp, ElevateBios centralized world-class research and development manufacturing center.
  • At Boston Childrens Hospital, we are proud of the foundation weve established as a leading innovator in cell and gene therapy, so collaborating with ElevateBio a company so well-positioned to change the face of cell and gene therapy forever is a natural fit into our overall vision, said David Williams, M.D., formerly Senior Vice President for Research and Chief Scientific Officer, currently Chief of Hematology / Oncology, Boston Children's Hospital.
  • Boston Childrens Hospital has a strong history of innovation in the cell and gene therapy sector through ground-breaking science and spinning out companies to deliver medicines to patients.

Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets

Retrieved on: 
Wednesday, June 23, 2021

The acquisition further enhances the Companys development pipeline of novel biologics that address immunology and immuno-oncology targets.

Key Points: 
  • The acquisition further enhances the Companys development pipeline of novel biologics that address immunology and immuno-oncology targets.
  • "We are delighted to enter into this license agreement with Sanford Burnham Prebys," said Garry Neil, Chief Scientific Officer of Cerecor.
  • This program reflects the increasing importance of novel immune checkpoints in health and disease.
  • I look forward to Cerecor rapidly advancing this program to the clinic.

Tumor Marker May Help Overcome Endocrine Treatment-Resistant Breast Cancer

Retrieved on: 
Thursday, May 20, 2021

b'LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy.

Key Points: 
  • b'LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy.
  • For decades, these tumors have been treated with anti-estrogen (endocrine) therapies to lower estrogen levels and help slow the cancer\'s growth.
  • "Unfortunately, this unleashes the detrimental effects of HER2, and patients become resistant to endocrine therapy--resulting in relapse, metastasis and death.
  • "\nThe National Cancer Institute (NCI) estimates that 281,550 women in the U.S. will be diagnosed with breast cancer in 2021, and 43,600 women will eventually die from the disease.

Children’s Hospital Los Angeles Chief Scientific Officer Named to California Stem Cell Research Body Governing Board

Retrieved on: 
Wednesday, April 7, 2021

Pat Levitt, PhD , Childrens Hospital Los Angeles (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM).

Key Points: 
  • Pat Levitt, PhD , Childrens Hospital Los Angeles (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM).
  • View the full release here: https://www.businesswire.com/news/home/20210407005237/en/
    Pat Levitt, PhD, Childrens Hospital Los Angeles (CHLA) Chief Scientific Officer and Director of The Saban Research Institute, has been appointed to the board that oversees the California Institute for Regenerative Medicine (CIRM).
  • A prolific pediatric researcher and scientist, Dr. Levitt oversees all research efforts at Childrens Hospital Los Angeles and The Saban Research Institute of CHLA .
  • The Saban Research Institute of Childrens Hospital Los Angeles is home to all basic, translational, clinical and community research conducted at the hospital, allowing proven discoveries to quickly reach patients.

Model Medicines announces AI-driven drug discovery partnership with Sanford Burnham Prebys

Retrieved on: 
Tuesday, March 23, 2021

LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.

Key Points: 
  • LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
  • The collaboration leverages Model Medicines' ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, in conjunction with Sanford Burnham Prebys' identification of novel antiviral targets and deep scientific expertise, to discover and develop new treatments for SARS-CoV-2 and other infectious diseases.
  • Model Medicines has created an infectious disease specific version of their ActivPred AI Drug Discovery Platform that focuses exclusively on identifying safe and effective, non-obvious therapeutics with activity against the novel biological targets identified by Sanford Burnham Prebys.
  • Model Medicines is transforming drug discovery by leveraging the historical compendium of drug development data, a drug and disease agnostic discovery platform, and unbiased AI to create Phase II/III ready drug candidates in months rather than years.

Instem Acquires Market Leader d-wise to Further Accelerate Life Science Development

Retrieved on: 
Monday, March 22, 2021

More than a growth-based acquisition, this can truly help transform the industry landscape, states Phil Reason, CEO at Instem.

Key Points: 
  • More than a growth-based acquisition, this can truly help transform the industry landscape, states Phil Reason, CEO at Instem.
  • By providing solutions across a wide area of the life science R&D continuum, Im certain that as part of Instem we will accelerate clinical development timelines and have an even broader impact on human health and wellbeing.
  • A global provider of leading software solutions and scientific insight services, Instem is helping clients bring their life enhancing products to market faster.
  • Across the entire drug development value chain, every day Instem solutions are meeting the rapidly expanding needs of life science organizations for data-driven decision making, leading to safer, more effective products.

ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors

Retrieved on: 
Thursday, March 18, 2021

ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the companys Chief Scientific Officer of Regenerative Medicine, Dr. Melissa Carpenter, has been appointed to the International Society for Stem Cell Research (ISSCR) Board of Directors.

Key Points: 
  • ElevateBio, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the companys Chief Scientific Officer of Regenerative Medicine, Dr. Melissa Carpenter, has been appointed to the International Society for Stem Cell Research (ISSCR) Board of Directors.
  • Collaboration across the stem cell professional community is critical to our ability to translate promising stem cell research and regenerative medicine science into treatments that can have dramatic benefit for global human health globally.
  • Her experience will be an asset to the Board as the field of stem cell science continues to rapidly evolve.
  • The International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic.

Buck Institute Names Malene Hansen as Chief Scientific Officer

Retrieved on: 
Wednesday, December 16, 2020

NOVATO, Calif., Dec. 16, 2020 /PRNewswire/ --The Buck Institute for Research on Aging is pleased to announce the appointment of Malene Hansen PhD to the position of Professor and Chief Scientific Officer.

Key Points: 
  • NOVATO, Calif., Dec. 16, 2020 /PRNewswire/ --The Buck Institute for Research on Aging is pleased to announce the appointment of Malene Hansen PhD to the position of Professor and Chief Scientific Officer.
  • In this role, and in conjunction with Eric Verdin, MD, Buck President and Chief Executive Officer, Hansen will be responsible for providing leadership and guiding the strategic scientific direction of the Institute.
  • Hansen comes to the Buck from Sanford Burnham Prebys Medical Discovery Institute where she is a professor in the Development, Aging and Regeneration Program.
  • The Buck Institute for Research on Aging is dedicated to ending the threat of age-related disease for this and future generations.

INDIGO's Preclinical Animal Model Platform Expands Zebrafish Offering

Retrieved on: 
Tuesday, October 6, 2020

STATE COLLEGE, Pa., Oct. 6, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems.

Key Points: 
  • STATE COLLEGE, Pa., Oct. 6, 2020 /PRNewswire-PRWeb/ --INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust portfolio of in vitro animal model assays with three additional first-in-class zebrafish model systems.
  • "This addition gives discovery scientists the ability to make key determinations on the correct animal model for their research with an ortholog that was not previously available before entering animal trials."
  • For researchers looking at nuclear receptor activity, zebrafish provide an attractive model as nearly all of the 48 human nuclear receptors are also present in the animal model.
  • With animal studies required by the FDA, selecting the animal model that provides the most representative human-surrogate is critical to assessing a potential drug's likelihood of unwanted effects.

Biocom Endorses Bond Measure to Fund Stem Cell Research in California

Retrieved on: 
Tuesday, August 18, 2020

Biocom, the association representing the California life science industry, today announced the endorsement of California Proposition 14, the Stem Cell Research Institute Bond Initiative.

Key Points: 
  • Biocom, the association representing the California life science industry, today announced the endorsement of California Proposition 14, the Stem Cell Research Institute Bond Initiative.
  • If passed, the initiative would result in California issuing $5.5 billion in general obligation bonds for the states stem cell research institute.
  • In 2004, California voters passed Proposition 71, which issued $3 billion in bonds to finance CIRM.
  • As of July 1, 2019, CIRM has suspended applications for new projects due to the depletion of Proposition 71 funds.